IART News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IA

Mkt Cap

$1.03B

Volume

674.01K

Next Earnings

October 21st

Loading chart

IA

IARTIntegra LifeSciences Holdings

IART

Pay with—

Available Balance0.00

IA

Mkt Cap

$1.05B

Volume

674.01K

Next Earnings

October 21st

Chart Financials Earnings News About Insider Filings

Stock Market Midday, Oct. 2: Stocks Rally as Weak Jobs Data Cools Fed Rate Hike BetsU.S. stock markets rallied on October 2, 2026, following weaker-than-expected September employment data showing only 29,000 jobs added and unemployment rising to 4.2%. The soft labor report reduced expectations for a Federal Reserve rate hike this month from 64% to 21%, boosting investor sentiment particularly in tech and growth stocks. The Nasdaq Composite hit a record high, while the S&P 500 and Dow Jones also gained.The Motley Fool · Oct 2, 2026

IART vs. PEN: Which Stock Is the Better Value Option?In a comparison of two medical instruments sector stocks, Integra LifeSciences (IART) emerges as the better value opportunity for investors compared to Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.62 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.18 and Value grade of D. IART's superior valuation metrics and improving earnings outlook make it the more attractive choice for value investors.Zacks Investment Research · Oct 1, 2026

Should You Continue to Hold IART Stock in Your Portfolio?Integra LifeSciences (IART) reported 1.6% organic growth in Specialty Surgery revenues driven by neurosurgery strength and improved supply reliability. Adjusted EPS rose 24.4% with margin expansion, and the company is ramping up Braintree production for a SurgiMend relaunch. However, elevated leverage at 4.1X and foreign exchange headwinds pressured full-year revenue guidance and financial flexibility.Zacks Investment Research · Sep 30, 2026

IART or PEN: Which Is the Better Value Stock Right Now?A comparison of two medical instruments companies reveals that Integra LifeSciences (IART) presents a more attractive value opportunity than Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.61 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.35 and Value grade of D. IART's stronger earnings estimate revisions and superior valuation metrics make it the preferred choice for value investors.Zacks Investment Research · Sep 29, 2026

Ultrasonic Aspirator Market Size Projected to Reach USD 376.32 Million by 2035 | SNS InsiderThe global ultrasonic aspirator market is valued at USD 194.03 million in 2025 and is projected to reach USD 376.32 million by 2035, growing at a CAGR of 6.87%. The U.S. market is expected to grow from USD 67.49 million to USD 118.90 million by 2035, driven by increasing adoption of advanced surgical technologies, rising neurosurgery procedures, and growing demand for minimally invasive surgeries. North America leads the market with 39.80% share, while Asia-Pacific registers the fastest growth at 8.83% CAGR.GlobeNewswire Inc. · Jul 28, 2026

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItConexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.Benzinga · May 22, 2026

Integra LifeSciences Reports First Quarter 2026 Financial ResultsIntegra LifeSciences reported Q1 2026 revenues of $391.9 million (up 2.4% reported, 1.3% organic) with improved gross margins and adjusted EPS of $0.54 versus $0.41 year-over-year. The company reaffirmed full-year revenue guidance of $1.662-$1.702 billion and raised adjusted EPS guidance to $2.40-$2.50 from $2.30-$2.40. Stuart Essig was appointed as the new President and CEO, and the company highlighted progress in manufacturing operations and product relaunches.GlobeNewswire Inc. · May 5, 2026

Tissue Engineering Market to Grow at 12.95% CAGR Reaching USD 27.59 Billion by 2031, Driven by Advances in Regenerative Medicine and Biomaterials, Says Mordor IntelligenceThe global tissue engineering market is projected to grow from USD 15.01 billion in 2026 to USD 27.59 billion by 2031, driven by advancements in regenerative medicine, biomaterials, and stem cell research. Key growth drivers include increasing demand for regenerative therapies, innovations in 3D bioprinting, rising prevalence of chronic diseases, and expanding applications in orthopedics, skin regeneration, and dental restoration. North America leads the market while Asia-Pacific emerges as a high-growth region.GlobeNewswire Inc. · Apr 24, 2026

[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global advanced wound closure market is projected to grow from USD 18.47 billion in 2025 to USD 32.54 billion by 2035, at a CAGR of 6.9%. Growth is driven by increasing surgical procedures, rising chronic wounds and diabetes cases, and technological innovations in surgical sealants, hemostats, and tissue adhesives. North America leads the market while Asia Pacific shows the highest growth potential.GlobeNewswire Inc. · Feb 2, 2026

Orthopedic Implants Market Outlook 2025–2034The global orthopedic implants market is valued at USD 52.86 billion in 2026 and is expected to reach USD 80.14 billion by 2034, growing at a 5.34% CAGR. North America leads the market while Asia-Pacific is the fastest-growing region. Joint reconstruction dominates by product type, with spinal implants showing significant growth potential. Key drivers include an aging population, rising musculoskeletal disorders, and technological innovations in 3D-printed and AI-enabled implants.GlobeNewswire Inc. · Jan 30, 2026

to start trading

IA

IARTIntegra LifeSciences Holdings

IART

Pay with—

Available Balance0.00

Your PositionYou don't own any IART yet.

Related Tickers

Earnings